Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
59
Frequently Asked Questions
What is Market Cap of Zevra Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Zevra Therapeutics Inc market cap is $435.05M.
What is the 52-week high for Zevra Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Zevra Therapeutics Inc 52 week high is $13.16 as of September 15, 2025.
What is the 52-week low for Zevra Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Zevra Therapeutics Inc 52 week low is $6.19 as of September 15, 2025.
What is Zevra Therapeutics Inc stock price today?
Zevra Therapeutics Inc stock price today is $7.23.
What was Zevra Therapeutics Inc stock price yesterday?
Zevra Therapeutics Inc stock price yesterday was $7.75.
What is the PE ratio of Zevra Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Zevra Therapeutics Inc’s P/E ratio is -142.46.
What is the Price-to-Book ratio of Zevra Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Zevra Therapeutics Inc P/B ratio is 3.6416.
What is the 50-day moving average of Zevra Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Zevra Therapeutics Inc 50-day moving average is $10.45.
How many employess does Zevra Therapeutics Inc has?